1. Scrip
  2. >>Business
  3. >>Financing

Riding On Exosome Potential, Evox Eyes Unicorn Status

UK Firm Completes £69.2m Series C Financing

 
• By Kevin Grogan

A financing round that was significantly oversubscribed by new and existing investors will help advance the Oxford-headquartered biotech's exosome therapeutics into the clinic and expand its technology platform.

A toy train pulling a cargo of money This picture could be a reference to 'money delivery', gravy train, cargo, freight. Also, money supply and transferring money or wiring money.
Oxford's Evox gets cash boost • Source: Archive

Evox Therapeutics Limited CEO Tony de Fougerolles has told Scrip that the UK firm's exosome expertise, strong pipeline and big pharma partnerships can help it become a 'unicorn' billion-dollar biotech.

He was speaking as Evox concluded a series C financing round that raised £69.2m ($95.4m) led by long-time backer Redmile...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 
• By Jessica Merrill

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.